U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H18FN3O2S.ClH.2H2O
Molecular Weight 395.877
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RIPASUDIL HYDROCHLORIDE DIHYDRATE

SMILES

O.O.Cl.C[C@H]1CNCCCN1S(=O)(=O)C2=CC=CC3=C2C(F)=CN=C3

InChI

InChIKey=CMDJNMACGABCKQ-XVSRHIFFSA-N
InChI=1S/C15H18FN3O2S.ClH.2H2O/c1-11-8-17-6-3-7-19(11)22(20,21)14-5-2-4-12-9-18-10-13(16)15(12)14;;;/h2,4-5,9-11,17H,3,6-8H2,1H3;1H;2*1H2/t11-;;;/m0.../s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C15H18FN3O2S
Molecular Weight 323.386
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25414122 | http://dwti.co.jp/english/business-outline/product-pipeline/glanatec

Ripasudil (K-115) is a selective Rho-associated coiled coil-containing protein kinase (ROCK) inhibitor. This compound, which was originally discovered by D. Western Therapeutics Institute, Inc., reduces intraocular pressure (IOP) by directly acting on the trabecular meshwork, thereby increasing conventional outflow through the Schlemm's canal. As a result of this mechanism of action, ripasudil may offer additive effects in the treatment of glaucoma and ocular hypertension when used in combination with agents such as prostaglandin analogues (which increase uveoscleral outflow) and β blockers (which reduce aqueous production). GLANATEC® (Ripasudil hydrochloride hydrate) ophthalmic solution 0.4% is launched in Japan for the treatment of glaucoma and ocular hypertension.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
51.0 nM [IC50]
19.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
GLANATEC

Approved Use

GLANATEC® (Ripasudil hydrochloride hydrate) ophthalmic solution 0.4% inhibits Rho kinase and promotes drainage of aqueous humor from main outflow. It consequently decreases intraocular pressure. It is usually used to treat glaucoma and ocular hypertension when other medicines for glaucoma have insufficient effect or can not be used.

Launch Date

2014
Primary
GLANATEC

Approved Use

GLANATEC® (Ripasudil hydrochloride hydrate) ophthalmic solution 0.4% inhibits Rho kinase and promotes drainage of aqueous humor from main outflow. It consequently decreases intraocular pressure. It is usually used to treat glaucoma and ocular hypertension when other medicines for glaucoma have insufficient effect or can not be used.

Launch Date

2014
PubMed

PubMed

TitleDatePubMed
Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits.
2014 Aug
Ripasudil: first global approval.
2014 Dec
Vascular Normalization by ROCK Inhibitor: Therapeutic Potential of Ripasudil (K-115) Eye Drop in Retinal Angiogenesis and Hypoxia.
2016 Apr 1
Ocular hypotensive effects of a Rho-associated protein kinase inhibitor in rabbits.
2017
Efficacy of Ripasudil as a Second-line Medication in Addition to a Prostaglandin Analog in Patients with Exfoliation Glaucoma: A Pilot Study.
2017 Jun
Time Course of Conjunctival Hyperemia Induced by a Rho-kinase Inhibitor Anti-glaucoma Eye Drop: Ripasudil 0.4.
2017 May
Efficacy and safety of adding ripasudil to existing treatment regimens for reducing intraocular pressure.
2018 Feb
Patents

Sample Use Guides

GLANATEC® (Ripasudil hydrochloride hydrate) ophthalmic solution 0.4% one drop twice daily
Route of Administration: Topical
Ripasudil but not fasudil significantly reduced VEGF-induced MYPT-1 phosphorylation in human retinal microvascular endothelial cells (HRMECs) at 30 μmol/L. Ripasudil significantly inhibited VEGF-induced HRMECs migration and proliferation.
Substance Class Chemical
Created
by admin
on Sat Dec 16 11:00:12 GMT 2023
Edited
by admin
on Sat Dec 16 11:00:12 GMT 2023
Record UNII
016TTR32QF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RIPASUDIL HYDROCHLORIDE DIHYDRATE
WHO-DD  
Common Name English
1H-1,4-DIAZEPINE, 1-((4-FLUORO-5-ISOQUINOLINYL)SULFONYL)HEXAHYDRO-2-METHYL-, MONOHYDROCHLORIDE, DIHYDRATE, (2S)-
Common Name English
RIPASUDIL HYDROCHLORIDE HYDRATE [JAN]
Common Name English
GLANATEC
Brand Name English
RIPASUDIL HYDROCHLORIDE DIHYDRATE [MI]
Common Name English
K-115-R
Code English
K-115
Code English
RIPASUDIL HYDROCHLORIDE HYDRATE
JAN  
Common Name English
Ripasudil hydrochloride dihydrate [WHO-DD]
Common Name English
ISOQUINOLINE, 4-FLUORO-5-(((2S)-HEXAHYDRO-2-METHYL-1H-1,4-DIAZEPIN-1-YL)SULFONYL)-, HYDROCHLORIDE, HYDRATE (1:1:2)
Systematic Name English
Code System Code Type Description
FDA UNII
016TTR32QF
Created by admin on Sat Dec 16 11:00:12 GMT 2023 , Edited by admin on Sat Dec 16 11:00:12 GMT 2023
PRIMARY
DRUG BANK
DBSALT002191
Created by admin on Sat Dec 16 11:00:12 GMT 2023 , Edited by admin on Sat Dec 16 11:00:12 GMT 2023
PRIMARY
CAS
887375-67-9
Created by admin on Sat Dec 16 11:00:12 GMT 2023 , Edited by admin on Sat Dec 16 11:00:12 GMT 2023
PRIMARY
PUBCHEM
11625386
Created by admin on Sat Dec 16 11:00:12 GMT 2023 , Edited by admin on Sat Dec 16 11:00:12 GMT 2023
PRIMARY
SMS_ID
100000164209
Created by admin on Sat Dec 16 11:00:12 GMT 2023 , Edited by admin on Sat Dec 16 11:00:12 GMT 2023
PRIMARY
EVMPD
SUB178572
Created by admin on Sat Dec 16 11:00:12 GMT 2023 , Edited by admin on Sat Dec 16 11:00:12 GMT 2023
PRIMARY
MERCK INDEX
m11878
Created by admin on Sat Dec 16 11:00:12 GMT 2023 , Edited by admin on Sat Dec 16 11:00:12 GMT 2023
PRIMARY
Related Record Type Details
ANHYDROUS->SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY